Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug opioid |
| gptkbp:actsOn |
opioid
opioid receptor agonist |
| gptkbp:ATCCode |
V03AB05
|
| gptkbp:CASNumber |
62-67-9
|
| gptkbp:category |
phenols
allyl compounds kappa-opioid receptor agonists morphinans mu-opioid receptor antagonists semisynthetic opioids |
| gptkbp:derivedFrom |
gptkb:morphine
|
| gptkbp:developedBy |
1950s
|
| gptkbp:discoveredBy |
gptkb:Everett_L._May
|
| gptkbp:hasInChIKey |
QIDNNJFMUCGCJL-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C19H21NO3
|
| gptkbp:hasSMILES |
C=CCN1CC[C@]23c4c5ccc(O)cc4O[C@H]2C=C[C@@H]3[C@H]1C5
|
| https://www.w3.org/2000/01/rdf-schema#label |
nalorphine
|
| gptkbp:isomerOf |
gptkb:morphine
|
| gptkbp:IUPACName |
(5α,6β)-17-allyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
|
| gptkbp:legalStatus |
withdrawn in many countries
|
| gptkbp:meltingPoint |
230–232 °C
|
| gptkbp:molecularWeight |
311.38 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201202
4417 DB01450 |
| gptkbp:replacedBy |
gptkb:naloxone
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous |
| gptkbp:sideEffect |
nausea
vomiting respiratory depression hallucinations dysphoria |
| gptkbp:synonym |
N-allylnormorphine
Nalline |
| gptkbp:UNII |
6YKS4Y3WQ7
|
| gptkbp:usedAs |
antidote to opioid overdose
diagnostic agent for opioid dependence |
| gptkbp:bfsParent |
gptkb:Schedule_III_controlled_substances
gptkb:levallorphan |
| gptkbp:bfsLayer |
7
|